An efficient and versatile CRISPR-Cas9 system for genetic manipulation of multi-drug resistant *Klebsiella pneumoniae*

Multi-drug resistant (MDR) *Klebsiella pneumoniae* remains an urgent public health threat. While whole-genome sequencing has helped identify genetic changes underlying resistance, functional validation remains difficult due to a lack of genetic manipulation systems for MDR *K. pneumoniae*. CRISPR-Cas9 has revolutionized molecular biology, but its use was only recently adapted in bacteria by overcoming the lack of genetic repair systems. We describe a CRISPR-Cas9/lambda recombineering system utilizing a zeocin resistance cassette allowing efficient and versatile genetic manipulation of *K. pneumoniae*.

**Step 1: 5-7 days**
Generate plasmid for your favorite gene (yfg) knockout

**Step 2: 2 days**
Transform CRISPR-yfg plasmid into *K. pneumoniae* isolate

**Step 3: 2 days**
Express CRISPR plasmid to induce DNA break and recombination

**Step 4: 3 days**
Isolate yfg mutant and cure CRISPR plasmid via serial passage

**HIGHLIGHTS**
Gene editing for multi-drug resistant *Klebsiella pneumoniae* utilizing CRISPR-Cas9

Description of plasmid design, cloning, genetic manipulation, and mutant confirmation

Approach allows for gene knockouts and single nucleotide polymorphism editing

“Scarless” editing allows for serial modifications in a single bacterial isolate
Protocol
An efficient and versatile CRISPR-Cas9 system for genetic manipulation of multi-drug resistant Klebsiella pneumoniae

Thomas H. McConville,¹,² Marla J. Giddins,¹ and Anne-Catrin Uhlemann¹,³,*

¹Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA
²Technical contact
³Lead contact
*Correspondence: au2110@columbia.edu
https://doi.org/10.1016/j.xpro.2021.100373

SUMMARY
Multi-drug resistant (MDR) Klebsiella pneumoniae remains an urgent public health threat. While whole-genome sequencing has helped identify genetic changes underlying resistance, functional validation remains difficult due to a lack of genetic manipulation systems for MDR K. pneumoniae. CRISPR-Cas9 has revolutionized molecular biology, but its use was only recently adapted in bacteria by overcoming the lack of genetic repair systems. We describe a CRISPR-Cas9/lambda recombineering system utilizing a zeocin resistance cassette allowing efficient and versatile genetic manipulation of K. pneumoniae.
For complete details on the use and execution of this protocol, please refer to McConville et al. (2020).

BEFORE YOU BEGIN
The purpose of this protocol is to generate a gene specific CRISPR plasmid to allow for a gene knockout or editing of single nucleotides in MDR Klebsiella pneumoniae. This protocol consists of two major sections.

The first section involves designing primers and cloning the CRISPR plasmid for the desired genetic change; either a 120–150 bp deletion or a single nucleotide polymorphism (SNP) insertion. The second section describes the gene deletion and editing procedures to generate the desired genetic change in K. pneumoniae isolates. Please read the entire protocol first and ensure you have all the necessary resources and reagents to carry out the entire protocol.

Of note, the restriction enzymes used for cloning are specific to the pUC19_CRISPR_ΔpmmrA plasmid (El-Halfawy et al., 2017; Jiang et al., 2013; Jiang et al., 2016; Jiang et al., 2015; Kovach et al., 1995; Zhao et al., 2016). AarI + Bsal will release the gRNA template DNA + zeocin cassette and Bsal + AhdI will release the homology cassette (Figure 1). The gRNA template DNA is transcribed into the gRNA, which aids the Cas9 protein in inducing a double-strand DNA break necessary for gene editing.
KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Chemicals, peptides, and recombinant proteins** |
| Zeocin selection antibiotic | Invivogen | Cat# Ant-zn-5b |
| Phusion high-fidelity DNA polymerase | NEB | Cat# M0530S |
| Taq DNA polymerase with standard Taq buffer | NEB | Cat# M0273S |
| AhdI restriction enzyme | NEB | Cat# R0584S |
| BsaI HF V2 restriction enzyme | NEB | Cat# R3733S |
| AarI restriction enzyme | Thermo Fisher | Cat# ER1581 |
| XbaI restriction enzyme | NEB | Cat# R0145S |
| T4 DNA ligase | NEB | Cat# M0202S |
| L-(+)-Arabinose | Thermo Fisher | Cat# A3256-25G |
| Molecular biology grade water | GE Life Sciences | Cat# SH30538.02 |
| Polymyxin B sulfate | Thermo Fisher | Cat# 2180029 |
| S.O.C. medium | Thermo Fisher | Cat# 15544034 |
| Mueller-Hinton Broth 2 for microbiology, cation-adjusted | Millipore Sigma | Cat# 90922 |

| **Critical commercial assays** |
| QIAprep spin mini-prep kit | Qiagen | Cat# 27104 |
| QIAquick gel extraction kit | Qiagen | Cat# 28115 |
| QIAquick PCR purification kit | Qiagen | Cat# 28104 |
| DNeasy Ultraclean microbial kit | Qiagen | Cat# 12224-250 |

| **Bacterial and virus strains** |
| One shot TOP10 chemically competent E. coli | Thermo Fisher | Cat# C404010 |

| **Experimental models: organisms/strains** |
| K. pneumoniae | ATCC | ATCC# BAA-1705D-5 |

(Continued on next page)
MATERIALS AND EQUIPMENT

Equipment and basic materials

This protocol requires standard microbiology laboratory equipment. This includes a PCR machine, microcentrifuge, a device for quantification of nucleic acids, for example a Qubit machine from Thermo Fisher, and two incubators, set at 30°C and 37°C, respectively.

Alternatives: We have optimized our protocol using enzymes from New England Biolabs, including the Phusion DNA polymerase, AhdI, BsaI, XbaI restriction enzymes and the T4 DNA ligase. Equivalent restriction enzymes and polymerases, from companies like Thermo Fisher or Promega, can likely be used interchangeably in this protocol.

Alternatives: This protocol uses Qiagen DNA extraction kits. These can be substituted with the corresponding kits from other suppliers, including Thermo Fisher, Zymo or Promega (plasmid mini-prep, agarose gel extraction, PCR clean up).

Solutions

- 10% arabinose – Dissolve 1 g of L-arabinose in 9 mL of water and slowly adjust the volume to 10 mL. Filter sterilize this solution. Storage condition: room temperature (20°C–25°C) for up to 6 months.
- 10% glycerol – Add 5 mL of glycerol to 45 mL of PCR grade H2O. Always prepare freshly.

STEP-BY-STEP METHOD DETAILS

Primer design (for gene knockouts)

© Timing: 2–3 h

Note: Please review Figure 2A for the primer design concept. This is a schematic of yfg (your favorite gene – the gene of interest) with all necessary primers and N20 sequences. This will help put in context the different steps for primer design. As a positive control, primers needed to generate a CRISPR plasmid for a mgrB gene knockout are included in Table 1.
1. Copy the first 200 bp (from the ATG start codon) of yfg into the https://crispr.dbcls.jp/ website and click “design.” Please see Figure 2B, which shows the sequence, annotated primers and annotated N20 sequences for the K. pneumoniae pmrA gene as a reference.

2. Choose two appropriate guide RNA N20 candidate sequences with a melting temperature of 70°C–75°C and a GC content between 40% and 60%.

   Note: Be sure to note which strand the N20 sequence is found on (forward or reverse complement strand). PAM sequences (NGG) are found at the 3' end of the N20 sequence. Two different guide RNA sequences are chosen for each knockout in case the efficiency of one is low in the knockout protocol. This allows for rapid use of the second guide RNA without having to re-design the CRISPR plasmid.

3. Click on the gRNA button next to the two selected N20 sequences to generate the full gRNA sequences. Change RNA to DNA by clicking the U→T button on the next page. This will provide the template DNA sequence for the gRNA.

4. Copy the first 40 bp of the DNA sequence:
   N20 Sequence + GTT TTA GAG CTA GAA ATA GC
   These sequences will be the gRNA_1_F and gRNA_2_F primers (see Figure 1 and Table 1).

5. Copy and paste these primer sequences into an excel spreadsheet based on Table 1.

6. Create a reverse complement of the two N20 sequences to generate the two gRNA_R primers.

   The additional sequence shown below is part of the pTAC promoter found directly upstream of the gRNA template DNA in the pUC19_Crispr_dpmrA plasmid.

   Reverse complement N20 Sequence + CCA CAC ATT ATA CGA GCC GA
   These sequences will be the gRNA_1 and gRNA_2_R primers.

7. Copy and paste these primer sequences into the excel spreadsheet.

8. Open the full gene sequence for the desired gene to be knocked out in a sequencing analyzing software, like SeqBuilder Pro from DNASTAR. Ensure there is at least 300 bp upstream of the start codon.
9. Annotate the two N20 sequences in the gene sequence. Ideally, the N20 sequences are within the first 150 bp of the gene.

10. Design primers to amplify two areas of homology for the puc19_CRISPR_Dyfg plasmid. Ideally the area of homology (upstream and downstream of the Cas9 cut site) is between 500–1,000 bp. For example, design the upstream homology primers to amplify approximately 250 bp upstream of the Cas9 cut site and the downstream homology to amplify 500 bp downstream of the Cas9 cut site (Figure 2). The sequence between the two areas of homology will be deleted following the knockout protocol.

**Note:** Four primers will be designed as indicated below. The two middle primers contain an imbedded restriction site. XbaI is shown below, but an alternative restriction site can be substituted. This site is used to ligate the two areas of homology together to create the full homology cassette. The 5’ and 3’ primers contain BsaI and AhdI sites respectively, allowing for ligation into the digested pUC19_CRISPR plasmid.

a. `yfg_Up_Hom_F_BsaI`
b. `yfg_Up_Hom_R_XbaI`
c. `yfg_Dwn_Hom_F_XbaI`
d. `yfg_Dwn_Hom_R_AhdI`

11. Choose 20 bp approximately 250 bp upstream of the yfg start codon. ATT + [BsaI site:GCT CTC GCG GT] + chosen 20 bp
This sequence will be: yfg_Up_Hom_F_Bsa.

12. Choose 20 bp around the start codon of yfg
   ATT + [Xba site: TCTAGA] + reverse complement of chosen 20 bp
   This sequence will be: yfg_Up_Hom_R_Xba.

13. Choose 20 bp approximately 120–150 bp from the start codon of yfg. Ensure the start of this primer is downstream of the second N20 sequence.
   ATT + [Xba site: TCTAGA] + chosen 20 bp
   This sequence will be: yfg_Dwn_Hom_F_Xba.

Note: The area between the yfg_Up_Hom_R_Xba and yfg_Dwn_Hom_F_Xba primers, which are used to amplify the two homology arms, will be the region within yfg that will be deleted in the final knockout strain. If the area to be deleted exceeds approximately 150 bp the efficiency of homologous recombination decreases.

14. Choose 20 bp approximately 500 bp downstream of the yfg_Dwn_Hom_F primer.
   ATT + [AhdI site: GAC CCC CTG TC] + reverse complement of chosen 20 bp
   This sequence will be: yfg_Dwn_Hom_R_AhdI.

15. Copy and paste the four primer sequences into the excel spreadsheet.

16. Choose 20–25 bp directly upstream of the yfg_Up_Hom_F primer sequence.
    This sequence will be: yfg_Del_F.

17. Choose 20–25 bp directly downstream of the yfg_Dwn_Hom_R_AhdI primer sequence.
    The reverse complement of this sequence will be: yfg_Del_R.

Note: These primers will be used after the knockout protocol is completed to screen for the appropriate knockout mutant. Mutants that have undergone the appropriate CRISPR-Cas9 gene editing will have a smaller band (based on the amount of the gene deleted) than the WT parent strain.

18. Create two primers with the two N20 sequences used in the two gRNA_F primers. These will be named N20_1_F and N20_2_F. The N20_1_F and N20_2_F and the yfg_Dwn_Hom_R_AhdI primers will create an approximately 1,800 bp band if the final plasmid has ligated together appropriately. Please see the plasmid cloning section for further details.

Note: These primers will be used to identify the correctly ligated final CRISPR plasmid after the ligation is transformed into chemically competent E. coli cells.

19. Primers CRISPR_Vector_F: 5’- GTT GTG AAG AAA AAG TGA ATG ATG TAG CCG and gRNA_Vector_R: 5’- ATT ACC GCG AGA CC G AAA CCA TTA TTA TCA TGA CAT TAA CC are included in the excel spreadsheet and are required to PCR amplify the gRNA cassette from the pUC19_CRISPR_ApmRA plasmid.

20. Order primers from IDTdna or an equivalent company that synthesizes DNA oligonucleotides.

Note: Table 1 includes validated primers for a knockout of the mgrB gene in K. pneumoniae. These primers can be used as a positive control. The knockout of mgrB induces polymyxin resistance, which is an easy to measure phenotype via broth microdilution or Etest.

Primer design (for SNP insertions)

© Timing: 2–3 h

Note: Please review the schematic in Figure 2C, which illustrates all the necessary primers and N20 sequence for a SNP insertion in an example yfg. For SNP insertions we use the same CRISPR plasmid backbone as for deletions, but replace the origin of replication with
pBBR1. This is a broad-host range, low copy number, origin of replication. The lower copy number origin of replication is more efficient for SNP editing. The pBBR1MCS2 plasmid can also be obtained via Addgene and the origin of replication can be amplified and used to replace the pUC origin of replication in the pUC19_CRISPR_DmrrA plasmid.

21. Copy the 200 bp downstream of the location of the desired SNP in yfg into the https://crispr.dbcls.jp/ website and click “design.”

22. Choose one appropriate guide RNA N20 candidate sequences based on the following parameters: a melting temperature of 70°C–75°C, a GC content between 40% and 60%, and approximately 30–60 bp from the desired SNP.

23. Follow steps 3–7 of the primer design section for gene knockouts to create the primers to amplify the gRNA template DNA for SNP insertion.

Note: For SNP insertion only one N20 sequence is necessary. The amplified homology cassette will be specific to the selected N20 sequence.

Note: Two primer pairs will be designed as indicated below. One of the two middle primers will contain the desired SNP and both will contain approximately 40 bp of overlapping sequence to allow for a downstream fusion PCR reaction to amplify the full homology cassette. This overlapping sequence will contain yfg gene sequence with a series of silent mutations that help to improve the efficiency of homologous recombination during the knock-in protocol (Figure 2C). The 5’ and 3’ primers will contain Bsal and AhdI sites respectively, allowing for future ligation into the digested pBBR1_CRISPR plasmid.

a. yfg_Up_Hom_F_Bsal
b. yfg_Up_Hom_SNP_Silent_R
c. yfg_Dwn_Hom_Silent_F
d. yfg_Dwn_Hom_R_AhdI

24. Choose 20 bp approximately 250–500 bp upstream of the desired SNP.
ATT + [Bsal site:GGTCCTCGG] + chosen 20 bp
This sequence will be: yfg_Up_Hom_F_Bsal.

25. Ensure the sequence analysis software displays the amino acid sequence for yfg in the desired reading frame.

26. Change the gene sequence to include the desired SNP.

27. Highlight the sequence directly downstream of the desired SNP and the end of the selected N20 + PAM (NGG) sequence. Identify all the codons that have a wobble bp and change the 3rd bp in these codons to insert a silent mutation. Ensure the resulting amino acid sequence (other than with the desired SNP) does not change.

28. Highlight approximately 15 bp upstream of the SNP and 45 bp downstream of the SNP to create an approximately 60 bp sequence. The reverse complement of this sequence will be: yfg_Up_Hom_SNP_Silent_R.

29. Identify an approximately 60 bp sequence that includes at least 15 bp of overlap with the yfg_Up_Hom_SNP_Silent_R primer, the modified N20 + PAM sequence and 15 bp of un-edited yfg sequence downstream of the N20 + PAM sequence. This sequence will be: yfg_Dwn_Hom_Silent_F.

30. Choose 20 bp approximately 250–500 bp downstream of the yfg_Dwn_Hom_Silent_F primer.
ATT + [AhdI site: GAC CCC CTG TC] + reverse complement of the chosen 20 bp
This sequence will be: yfg_Dwn_Hom_R_AhdI.

31. Choose 20–25 bp between the SNP and the N20 sequence that contains the inserted silent mutations. This sequence will be: yfg_SNP_Confirm_F.

32. Choose 20–25 bp directly downstream of the yfg_Dwn_Hom_R_AhdI primer. The reverse complement of this will be: yfg_SNP_Confirm_R.
Note: These two primers will be used to confirm the successful homologous recombination of the yfg homology into the genome. This primer combination will only amplify genomic DNA that has been modified with the completed yfg SNP CRISPR plasmid.

33. Order primers from IDTdna or an equivalent company that synthesizes DNA oligonucleotides.

CRISPR plasmid cloning

© Timing: 5–7 days

34. Day 1: PCR amplify the two areas of homology (Up homology, Down homology) for the homology cassette and the two gRNA PCR products for the gRNA cassettes. Use the Phusion high-fidelity DNA polymerase.
   a. Primer Set + Template:
      i. yfg_Up_Hom_F_BsaI + yfg_Up_Hom_R_XbaI – Template: 50–100 ng of genomic DNA
         Expected product size: approximately 250 bp
      ii. yfg_Dwn_Hom_F_XbaI + yfg_Dwn_Hom_R_AhdI – Template: 50–100 ng of genomic DNA
         Expected product size: approximately 500 bp
      iii. CRISPR_Vector_F + gRNA_1_R – Template: 50–100 ng of pUC19_CRISPR_DpmrA
         Expected product size: approximately 380 bp
      iv. gRNA_1_F + gRNA_Vector_R – Template: 50–100 ng of pUC19_CRISPR_DpmrA
         Expected product size: approximately 1100 bp

Note: Please see Figures 1 and 2 for visualization of the expected PCR products. Since the PCR products will be used in downstream applications we recommend a 50 µL reaction volume following the NEB Phusion polymerase protocol. The PCR parameters shown below can be used for all four PCR reactions.

| Reagent                  | Homology cassette up | Homology cassette down | gRNA cassette forward | gRNA cassette reverse |
|--------------------------|----------------------|------------------------|-----------------------|----------------------|
| H₂O                      | Variable             | Variable               | Variable              | Variable             |
| Phusion 5X Reaction Buffer| 10 µL                | 10 µL                  | 10 µL                 | 10 µL                |
| Primer 1                 | 2.5 µL yfg_Up_Hom_F_BsaI | 2.5 µL yfg_Dwn_Hom_F_XbaI | 2.5 µL gRNA_1_F | 2.5 µL CRISPR_Vector_F |
| Primer 2                 | 2.5 µL yfg_Up_Hom_R_AhdI | 2.5 µL yfg_Dwn_Hom_R_AhdI | 2.5 µL gRNA_Vector_R | 2.5 µL gRNA_1_R |
| 2.5 mM dNTPs             | 4 µL                 | 4 µL                   | 4 µL                  | 4 µL                 |
| Template                 | 50–100 ng genomic DNA | 50–100 ng genomic DNA | 50–100 ng CRISPR Plasmid DNA | 50–100 ng CRISPR Plasmid DNA |
| Phusion Polymerase       | 0.5 µL               | 0.5 µL                 | 0.5 µL                | 0.5 µL               |
| Total                    | 50 µL                | 50 µL                  | 50 µL                 | 50 µL                |

Note: These PCR reactions will be carried out in a 50 µL reaction volume following the NEB Phusion polymerase protocol. The PCR cycling conditions below are recommended.

| Step                     | Temperature | Time  | Cycles |
|--------------------------|-------------|-------|--------|
| Initial Denaturation     | 98 °C       | 30 s  | 1      |
| Denaturation             | 98 °C       | 10 s  | 35 cycles |
| Annealing                | 55 °C       | 30 s  |        |
| Extension                | 72 °C       | 40 s  |        |
| Final Extension          | 72 °C       | 10 min| 1      |
| Hold                     | 4 °C        |       |        |
35. Load all 50 µL of each PCR product on a 1% agarose gel to visualize and ensure the appropriate band sizes indicated above.

**Note:** The size of the homology arms will depend on the primers chosen above.

36. Gel purify the four PCR products according to the QIAquick gel purification kit protocol (https://www.qiagen.com/us/resources/resourcedetail?id=a72e2c07-7816-436f-b920-98a0ede5159a&lang=en). Elute the DNA product in 45 µL of H2O. Store the two gRNA PCR products at −20°C.

37. Set up a restriction enzyme digestion with XbaI for the up and down areas of homology. Incubate at 37°C for approximately 1 h.

38. Clean up the two restriction enzyme digests according to the QIAquick PCR purification kit protocol (https://www.qiagen.com/us/resources/resourcedetail?id=a72e2c07-7816-436f-b920-98a0ede5159a&lang=en).

39. Quantify the concentration of the two areas of homology and set up a ligation at a 1:1 molar ratio of each with T4 DNA ligase. Follow the protocol from NEB to setup a 20 µL ligation (https://www.neb.com/protocols/0001/01/01/dna-ligation-with-t4-dna-ligase-m0202). Allow the ligation to incubate at room temperature (20°C–25°C) for approximately 1 h.

**Note:** This ligation reaction will generate three different product sizes, assuming 100% ligation efficiency. A 500 bp product (up homology + up homology) a 750 bp product (up homology + down homology) and a 1000 bp product (down homology + down homology). The 750 bp product is the desired homology cassette that will induce the desired deletion after homologous recombination into yfg.

40. Run the entire ligation reaction on a 1% agarose gel, allowing for appropriate separation of the three expected bands: 500 bp, 750 bp and 1,000 bp.

41. Gel purify the 750 bp band using the QIAquick gel purification kit. Elute product in 30 µL of H2O.

**Note:** For amplification of the homology for a SNP insertion the amplification and gel extraction steps are the same. Since the second PCR reaction utilizes a fusion PCR technique, restriction enzyme digestion + ligation is not necessary. It will be necessary, however, to quantify the concentration of the two areas of homology after gel purification to generate a 1:1 molar ratio in the downstream fusion PCR reaction.

42. Set up PCR reactions using the Phusion polymerase to amplify the full gRNA cassette, the ligated yfg homology cassette or the yfg homology cassette for a SNP insertion. Since these PCR products will be used for downstream cloning, we recommend a 100 µL reaction to ensure enough product.
   a. **yfg**_Up_Hom_F_BsaI + **yfg**_Dwn_Hom_R_AhdI (gene deletion primers)– Template: 1 µL of gel purified ligation. Expected band size: ~750 bp
   b. **yfg**_Up_Hom_F_BsaI + **yfg**_Dwn_Hom_R_AhdI (SNP insertion primers)– Template: gel purified PCR products at a 1:1 molar ratio (10–100 ng of DNA) – Expected band size – depends on selected primers
   c. CRISPR_Vector_F + gRNA_Vector_R – Template: the two gRNA PCR products at a 1:1 molar ratio (10–100 ng of DNA) – Expected Band size: approximately 1500 bp
Note: The PCR reactions to generate the full gRNA cassette and the SNP homology are fusion PCR reactions. The N20 sequence in the gRNA_F primer and the reverse complement of the N20 sequence in the gRNA_R primer will bind via homology allowing for amplification of the full 1500 bp cassette. Similarly, the overlapping area of silent mutations in the yfg_Up_Hom_SNP_Silent_R and yfg_Dwn_Hom_Silent_F primers will bind via homology allowing for amplification of the full cassette (Figure 2C). The PCR parameters below can be used for all three PCR reactions.

**PCR reaction setup for homology and gRNA cassettes**

| Reagent | Full homology cassette – gene deletion | Full homology cassette – SNP insertion | Full gRNA cassette |
|---------|--------------------------------------|--------------------------------------|-------------------|
| H2O     | Variable                             | Variable                             | Variable          |
| Phusion 5X Reaction Buffer | 10 µL | 10 µL | 10 µL |
| Primer 1 | 2.5 µL yfg_Up_Hom_F_BsaI | 2.5 µL yfg_Up_Hom_F_BsaI | 2.5 µL CRISPR_Vector_F |
| Primer 2 | 2.5 µL yfg_Dwn_Hom_R_AhdI | 2.5 µL yfg_Dwn_Hom_R_AhdI | 2.5 µL gRNA_Vector_R |
| 2.5 mM dNTPs | 4 µL | 4 µL | 4 µL |
| Template | 1 µL ligated homology | 1.1 molar ratio of the Up / Down homology PCR products | 1.1 molar ratio of the two gRNA PCR products |
| Phusion Polymerase | 0.5 µL | 0.5 µL | 0.5 µL |
| Total | 50 µL | 50 µL | 50 µL |

**Note:** The PCR reactions to generate the full gRNA cassette and the SNP homology are fusion PCR reactions. The N20 sequence in the gRNA_F primer and the reverse complement of the N20 sequence in the gRNA_R primer will bind via homology allowing for amplification of the full 1500 bp cassette. Similarly, the overlapping area of silent mutations in the yfg_Up_Hom_SNP_Silent_R and yfg_Dwn_Hom_Silent_F primers will bind via homology allowing for amplification of the full cassette (Figure 2C). The PCR parameters below can be used for all three PCR reactions.

**PCR cycling parameters for the Phusion polymerase: CRISPR plasmid cloning**

| Step         | Temperature | Time  | Cycles |
|--------------|-------------|-------|--------|
| Initial Denaturation | 98°C       | 30 s  | 1      |
| Denaturation  | 98°C       | 10 s  | 35 cycles |
| Annealing    | 55°C       | 30 s  |        |
| Extension    | 72°C       | 1 min |        |
| Final Extension | 72°C     | 10 min | 1      |
| Hold         | 4°C        |       |        |

**Note:** This is an appropriate stopping point for day 1. The PCR reactions will be stable overnight, 12–18 h, in the PCR machine at 4°C–12°C, or in the refrigerator.

43. **Day 2:** Run each of the 100 µL PCR reactions (homology cassette and gRNA cassette) on a 1% agarose gel. Gel purify the cassettes using the QIAquick gel purification kit. Expected band sizes are:
   a. The gRNA cassette: approximately 1,500 bp,
   b. yfg homology cassette for knockout: 750 bp,
   c. yfg homology cassette for SNP insertion: variable.

**Note:** With the gRNA cassette amplification, the fusion PCR technique will yield several smaller, non-specific bands. Make sure to only extract the top most band corresponding to the full 1,500 bp cassette.

44. Set up three separate digests shown below.
   a. gRNA cassette: AarI
   b. yfg homology cassette: AhdI and BsaI HF-V2
   c. pUC19_CRISPR_dprrA: AarI

Allow the digests to incubate for 4 h at 37°C.
45. Purify the three digestion reactions using the QIAquick PCR purification kit. Elute the digestion reactions in 45 μL of H₂O. Store the yfg homology cassette at −20°C.

46. Set up secondary digestion reactions for the gRNA cassette and the CRISPR plasmid vector.
   a. gRNA cassette AarI digested: BsaI HF-V2
   b. pUC19_CRISPR_ΔpmrA AarI digested: AhdI

   **Note:** The secondary BsaI digest in the gRNA cassette allows it to be ligated to the 5’ end of the homology cassette in the ligation reaction described below. The secondary AhdI digest in the pUC19_CRISPR_ΔpmrA plasmid will release the pmrA gRNA and homology cassettes. The flanking AarI and AhdI sites on the yfg gRNA and homology cassettes will ligate into the digested pUC19_CRISPR_ΔpmrA plasmid.

   Allow the digests to incubate at 37°C for 4 h.

47. Purify the two repeat digestion reactions using the QIAquick PCR purification kit. Elute the digestion reactions in 30 μL of H₂O.

48. Quantify the DNA concentration of the three digestion products.

   **Pause point:** This is a safe stopping point. The purified DNA products can be stored at −20°C for several weeks.

49. Set up a 20 μL ligation reaction using the T4 DNA ligase. Ensure a 1:3:3 molar ratio of the pUC19 CRISPR vector : the gRNA cassette : the yfg homology cassette. Use at least 100 ng of the pUC19_CRISPR vector. Incubate the ligation at 16°C for 12–18 h (overnight).
CRITICAL: Since the final plasmid is between 11,000 to 12,000 bp and this ligation reaction includes a vector and two inserts, the final efficiency will be low. As a result, the extended incubation for 12–16 h (overnight) is necessary to maximize transformation efficiency.

50. **Day 3:** Heat inactivate the ligation reaction at 65°C for 10 min.
51. Store reaction at –20°C until ready for transformation.
52. Transform 5 µL of the ligation reaction into an aliquot of TOP10 cells. Follow the provided protocol from Invitrogen for chemical transformation (https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FSLG%2Fmanuals%2Foneshottop10_man.pdf&title=T25lIFNob3QgVE9QMTAgQ29tcGV0ZW50IE1lbGlh).
53. Add 5 µL of the ligation reaction to a thawed aliquot of TOP10 cells on ice.
54. Incubate the TOP10 Cells on ice for 30 min.
55. Heat shock the TOP10 cells for 30 s at 42°C. Let sit on ice for 2 min.
56. Add 250 µL of S.O.C. media to the TOP10 cells and shake at 37°C and 220 RPM for 1 h.
57. Spin down the transformation reaction in a microcentrifuge at 4,000 × g for 10–15 min.
58. Re-suspend the bacterial pellet in 50–100 µL of residual S.O.C. media.
59. Spread plate the transformation reaction on Luria Bertani (LB) plates supplemented with zeocin at 37.5 µg/ml.
60. Incubate plate at 37°C overnight (12–18 h).
61. **Day 4:** Perform colony PCR to identify resulting transformants that contain the desired final pUC19_CRISPR_yfg plasmid.
62. Pick 24–48 colonies and re-suspend in 25 µL of H2O.
63. Set up a PCR master mix using the gRNA_N20_F primer(s) and the yfg_Dwn_Hom_R_AhdI primer and a standard Taq polymerase. NEB Taq polymerase works efficiently for this reaction. Follow the NEB protocol for a 25 µL reaction (https://www.neb.com/protocols/0001/01/taq-dna-polymerase-with-standard-taq-buffer-m0273)
64. Add 1 µL of each picked colony as template for the PCR reaction.

**Note:** The gRNA_N20_F primer(s) only contains the N20 sequence found in the gRNA cassette(s). This primer combined with yfg_Dwn_Hom_R_AhdI primer will yield a 1,800–2,000 bp product if the two inserts ligated into the pUC19_CRISPR vector in the appropriate orientation. See below for the appropriate PCR reaction conditions using the NEB Taq polymerase.

| Step                | Temperature | Time   | Cycles |
|---------------------|-------------|--------|--------|
| Initial Denaturation| 95°C        | 30 s   | 1      |
| Denaturation         | 95°C        | 30 s   | 35 cycles |
| Annealing            | 55°C        | 30 s   |        |
| Extension            | 68°C        | 2 min  |        |
| Final Extension      | 68°C        | 10 min | 1      |
| Hold                 | 4°C         |        |        |

65. Run the PCR products on a 1% agarose gel.
66. Identify the corresponding picked colonies that yielded a 1,800–2,000 bp band indicating the desired final pUC19_CRISPR_yfg plasmid.

**Note:** We often see between 50–100 colonies on the transformation plate. In our experience approximately 10%–50% of picked colonies contain the desired plasmid.
67. Inoculate the remaining volume of the PCR-confirmed picked colonies into 5 mL of LB broth supplemented with 37.5 μg/mL of zeocin. Incubate shaking at 220 RPM and 37°C overnight, 12–18 h.

68. Day 5: Mini-prep the overnight cultures using the QIAprep plasmid mini kit (https://www.qiagen.com/us/resources/resourcedetail?id=22df6325-9579-4aa0-819c-788f73d81a09&lang=en). Elute the final CRISPR plasmid in 40 μL of H2O.

69. Quantify the DNA concentration of the resulting plasmids. Expected concentration: 50–200 ng/μL of DNA.

70. Send the prepped plasmids for Sanger sequencing to ensure the desired sequence is present.

Note: Send three sequencing reactions for each plasmid to confirm the most important portions of the plasmid. The CRISPR_Vector_F primer can be used to sequence the gRNA template DNA and ensure the new N20 sequence has been inserted. The yfg_Up_Hom_F_BsaI primer can be used to sequence the yfg homology ensuring the up / down areas of homology are in the correct orientation with the imbedded XbaI site, or the desired SNP and silent mutations are present. Finally, the M13R primer, which is a universal primer at most Sanger sequencing companies, can be used to ensure that sequences for the araBAD promoter and the cas9 gene are intact.

MgrB knockout/SNP editing and mutant confirmation

© Timing: 7–10 days

71. Days 1–3: Create an electrocompetent stock of the K. pneumoniae isolate to be modified. Streak the desired isolate onto a non-selective LB plate. Incubate at 37°C overnight for 12–16 h.

72. Pick a single colony and start an overnight seed culture in 5 mL of non-selective LB broth. Incubate shaking at 220 RPM and 37°C overnight, 12–18 h.

73. Sub-culture the overnight culture into 25 mL of LB at a 1:100 dilution.

74. Grow the culture, shaking at 220 RPM and 37°C until an OD600 of 0.35–0.45 is reached.

75. Chill the culture on ice for 20 min.

76. Spin the culture down at 4,000 × g for 20 min and pour off the supernatant.

77. Re-suspend the bacterial pellet in 2.5 mL of ice-cold 10% glycerol.

78. Spin the suspension down at 4,000 × g for 20 min and discard the supernatant.

79. Repeat the wash step with 2.5 mL of ice-cold 10% glycerol.

80. Spin the suspension at 4,000 × g for 20 min and pour off supernatant.

81. Resuspend the bacterial pellet in 330 μL of ice-cold 10% glycerol.

82. Aliquot 50 μL of the re-suspension into 0.5 or 1.5 mL microcentrifuge tubes.

83. Snap freeze the 50 μL aliquots in liquid nitrogen and store at −80°C for future use.

84. Days 3–4: Electroporate sequence confirmed CRISPR plasmid into the electrocompetent stock and confirm uptake of plasmid via colony PCR. Thaw a 50 μL aliquot of the electrocompetent isolate on ice.

85. Add 100–200 ng of the pUC19_CRISPR_dmgrB or pBBR1_CRISPR_yfg_SNP plasmid (no more than 5 μL total) to the thawed cells.

86. Transfer the re-suspension to an ice-cold 1 mm cuvette.

87. Electroporate with a voltage of 1800 V, capacitance of 25 μF and a resistance of 200 ohms.

88. Immediately add 1 mL of S.O.C media. Recover cells shaking at 220 RPM and 37°C for 1 h.

89. Spin down the bacterial culture at 4,000 × g for 10 min. Re-suspend the bacterial pellet in 50–100 μL of residual media.

90. Plate the entire re-suspension onto LB supplemented with zeocin at 1000 μg/mL. Incubate at 37°C overnight, 12–18 h.
**Note:** Plating a lower concentration of the transformation reaction (only 50 μL or 1:10 / 1:100 dilutions) may be necessary depending on the underlying competency of the *K. pneumoniae* strain to be modified. The ST258 carbapenem resistant *K. pneumoniae* isolates are minimally competent and thus require plating a higher concentration of the transformation reaction. Additionally, it may be necessary to change the final concentration of zeocin in the LB plates. Performing a broth microdilution with zeocin and the isolate to be modified will allow for more precise prediction of the isolate’s minimum inhibitory concentration (MIC) to zeocin. 1000 μg/mL is an appropriate zeocin concentration for the majority of the carbapenem resistant ST258 *K. pneumoniae* isolates.

91. Pick between 8 and 32 colonies on the resulting plate for colony PCR to confirm the CRISPR plasmid has been taken up.

**Note:** There is low-level background resistance to zeocin that develops in vitro for some of the *K. pneumoniae* isolates. As a result, this colony PCR step to confirm the desired plasmid has been taken up by the *K. pneumoniae* isolate is necessary.

92. Re-suspend the picked colonies in 25 μL of water.

93. Use the CRISPR_Vector_F and gRNA_Vector_R primers to confirm the presence of the CRISPR plasmid using colony PCR with standard Taq polymerase. Follow the NEB protocol for a 25 μL reaction ([https://www.neb.com/protocols/0001/01/01/taq-dna-polymerase-with-standard-taq-buffer-m0273](https://www.neb.com/protocols/0001/01/01/taq-dna-polymerase-with-standard-taq-buffer-m0273)). The pUC19_CRISPR_dpmrA plasmid can be used as a positive control. The expected band is approximately 1,500 bp. Use 1 μL of each picked colony as a template. Below are the appropriate PCR reaction conditions.

| Step               | Temperature | Time   | Cycles |
|--------------------|-------------|--------|--------|
| Initial Denaturation| 95°C        | 30 s   | 1      |
| Denaturation       | 95°C        | 30 s   | 35 Cycles |
| Annealing          | 55°C        | 30 s   |        |
| Extension          | 68°C        | 1:30 min |      |
| Final Extension    | 68°C        | 10 min | 1      |
| Hold               | 4°C         |        |        |

94. Run the resulting PCR products on a 1% agarose gel to identify colonies that harbor the CRISPR plasmid, demonstrated by a 1,500 bp band.

95. Store the picked colonies that have taken up the plasmid at –20°C for future use in the knockout protocol.

96. **Day 5: MgrB knockout or SNP editing protocol.** Inoculate 10 μL of each picked colony into two 5 mL cultures of LB supplemented with 1000 μg/mL of zeocin. Label one culture “induced” and one culture “control”.

**Note:** The knockout and SNP editing protocols are identical for either a deletion mutant or a SNP mutant.

⚠️ **CRITICAL:** There is variability in the efficiency of the CRISPR-Cas9 protocol. As a result, choosing 2–4 colonies that contain the CRISPR plasmid to use in the knockout / SNP editing protocol allows for higher likelihood of success.

97. Grow the two cultures per picked colony shaking at 220 RPM and 30°C for 2 h.
98. After 2 h add 100 μL of 10% arabinose to the “induced” culture to achieve a final concentration of 0.2% arabinose. The arabinose will induce the expression of the cas9 and lambda red recombineering genes (see below).

99. Grow the induced and control cultures shaking at 220 RPM and 30°C for 6–8 h.

Note: Since the plasmid contains two arabinose promoters, one upstream of the cas9 gene and one upstream of the lambda red recombineering genes, only the induced cultures will express the CRISPR-Cas9 machinery. Since the double-strand break induced by the combination of Cas9 and the mgrB gRNA is toxic to growing bacterial cells, only those isolates that undergo homologous recombination with the mgrB homology will survive. Since the homologous recombination event is not 100% efficient, the induced culture should be significantly less turbid than the control culture (Figure 3).

100. Measure the OD_{600} of the induced and control cultures after the 6–8 h of growth. If the OD_{600} is greater than 0.10 (visibly turbid) make a 1:100 dilution of the cultures to ensure single colonies upon plating. If the OD_{600} is less 0.1 (not visibly turbid) plate directly from the resulting culture

101. Plate 10 μL of the induced culture dilution on LB + 1000 μg/mL of zeocin + 0.2% arabinose and 10 μL of the control culture dilution on LB + 1000 μg/mL of zeocin only. Incubate the plates at 30°C overnight, 12–18 h.

102. Day 6: mgrB knockout mutant or SNP edited mutant confirmation. Perform colony PCR on 24–48 colonies from the induced plate using the mgrB_Del F/R primers to detect a deletion within the genome. Use the standard Taq polymerase and follow the NEB protocol for a 25 μL reaction (https://www.neb.com/protocols/0001/01/01/taq-dna-polymerase-with-standard-taq-buffer-m0273). Run a control reaction with a colony of the wild type parent K. pneumoniae isolate. Use 1 μL of each picked colony as a template.

Note: These primers bind genomic DNA upstream and downstream of the homology contained in the pUC19_Crispr_dmgrB plasmid, thus will not amplify the plasmid and will only amplify genomic DNA (see Figure 2A). If the double-strand break and homologous recombination event have occurred there will be a deletion in the genomic DNA and the PCR band from the desired mutant will be smaller than from the WT parent isolate (Figure 4).
Note: For confirmation of SNP editing the yfg\_SNP\_Confirm_F/R primers are used. The forward primer binds within the area of homology containing the silent mutations; only binding genomic DNA of the desired mutant, or the pBBR1\_CRISPR\_yfg\_SNP plasmid. The reverse primer will only bind genomic DNA and as a result only the desired mutant will produce a band with this primer set. See Figure 2C for a schematic to see relative locations of primer binding. Below are the PCR reaction conditions for both the knockout and SNP editing confirmation using standard Taq polymerase.

| PCR cycling parameters for standard Taq polymerase: mutant confirmation | Temperature | Time | Cycles |
|---------------------------------------------------------------|-------------|------|--------|
| **Step**                                                      |             |      |        |
| Initial Denaturation                                          | 95°C        | 30 s | 1      |
| Denaturation                                                  | 95°C        | 30 s | 35 Cycles |
| Annealing                                                     | 55°C        | 30 s |        |
| Extension                                                     | 68°C        | 1 min|        |
| Final Extension                                               | 68°C        | 10 min| 1     |
| Hold                                                          | 4°C         |      |        |

103. Identify the picked colonies that contain the appropriate deletion or SNP based on the PCR reaction. Streak up to 4 on non-selective LB agar and incubate at 37°C overnight, 12–18 h.

104. Days 7–9: Confirming the Mutant via Sanger Sequencing, curing the CRISPR plasmid and Stocking the Final Mutant. Pick 4–8 colonies from each sub-cultured mutant and repeat the
colony PCR with the mgrB_Del_F/R or yfg_SNP_Confirm_F/R primers to ensure the mutation is stable.

105. Send 1–4 PCR products for Sanger sequencing to confirm the deletion. Use the mgrB_Del_F or yfg_SNP_Confirm_R primers to confirm the desired mutation. This will confirm the presence of the knockout or SNP in the genomic DNA.

106. Streak the same 1–4 picked colonies onto non-selective LB agar. Incubate at 37°C overnight, 12–18 h.

107. Pick up to 48 colonies from the plates that were sequence confirmed to run colony PCR to evaluate for loss of the CRISPR plasmid. Use the CRISPR_Vector_F and gRNA_Vector_R primers with standard Taq polymerase in a 25 μL reaction. Follow the NEB protocol for a 25 μL reaction (https://www.neb.com/protocols/0001/01/01/taq-dna-polymerase-with-standard-taq-buffer-m0273). Below are the appropriate PCR reaction conditions.

| Step         | Temperature | Time  | Cycles |
|--------------|-------------|-------|--------|
| Initial Denaturation | 95°C        | 30 s  | 1      |
| Denaturation  | 95°C        | 30 s  | 35 Cycles |
| Annealing    | 55°C        | 30 s  |        |
| Extension    | 68°C        | 1:30 min |       |
| Final Extension | 68°C        | 10 min | 1      |
| Hold         | 4°C         |       |        |

**Note:** After one sub-culture onto non-selective media, loss of the CRISPR plasmid occurs in 1%–5% of picked colonies. After two rounds of sub-culturing onto non-selective media this increases to approximately 20%–50% of picked colonies. Screening 48 picked colonies will likely yield at least one colony that lacks a band with the CRISPR_Vector_F / gRNA_Vector_R primers, indicating loss of the CRISPR plasmid.

108. Select 1–2 picked colonies that lack the CRISPR plasmid and inoculate these colonies into 5 mL of LB broth. Shake at 220 RPM and 37°C overnight 12–18 h.

109. Stock the mutant in a final concentration of LB + 25% glycerol. Store at −80°C for future use.

**Note:** We frequently also carry out whole genome sequencing of edited isolates to confirm the deletion, true loss of the plasmid and to ensure no off-target effects have occurred. This can be performed with multiple commercial agencies including Genewiz (https://www.genewiz.com/en/Public/Services/Next-Generation-Sequencing/Whole-Genome-Sequencing).

**Note:** The resulting mgrB deletion mutant will be polymyxin resistant; an easy way to test the resulting phenotype is to perform a broth microdilution to polymyxin B as described below.

110. Dilute 55 mg of polymyxin B sulfate in 8.27 mL of molecular grade water. This makes a 5120 μg/mL stock solution. Vortex and separate into 500 μL aliquots.

111. Create 11 solutions in cation-adjusted Mueller-Hinton broth (CAMHB) based on the table below:

| Solution  | CAMHB volume | Volume of solution | Polymyxin B concentration |
|-----------|--------------|--------------------|---------------------------|
| Solution 1| 4.5 mL       | 0.5 mL of 5120 μg/mL polymyxin B | 512 μg/mL |
| Solution 2| 2 mL         | 2 mL of solution 1 | 256 μg/mL |

(Continued on next page)
This will create enough solution for approximately 4 broth microdilution 96 well plates. Add 100 μL of the solutions to a 96 well round bottom cell culture plate based on the table below:

| Solution | CAMHB volume | Volume of solution | Polymyxin B concentration |
|----------|--------------|--------------------|---------------------------|
| Solution 3 | 3 mL | 1 mL of solution 1 | 128 μg/mL |
| Solution 4 | 7 mL | 1 mL of solution 1 | 64 μg/mL |
| Solution 5 | 2 mL | 2 mL of solution 4 | 32 μg/mL |
| Solution 6 | 3 mL | 1 mL of solution 4 | 16 μg/mL |
| Solution 7 | 7 mL | 1 mL of solution 4 | 8 μg/mL |
| Solution 8 | 2 mL | 2 mL of solution 7 | 4 μg/mL |
| Solution 9 | 3 mL | 1 mL of solution 7 | 2 μg/mL |
| Solution 10 | 7 mL | 1 mL of solution 7 | 1 μg/mL |
| Solution 11 | 2 mL | 2 mL of solution 10 | 0.5 μg/mL |

113. Wrap plates in parafilm and store at −80°C for future use for up to 2 weeks.
114. Re-suspend bacterial isolates from picked colonies into 3 to 5 mL normal saline in a disposable culture glass tube to reach a 0.5 McFarland standard of the bacterial suspension.
115. Dilute 15 μL of this 0.5 McFarland bacterial suspension in 1485 μL of CAMHB.
116. Inoculate 100 μL of this dilution into one row of the 96 well broth microdilution plate. Each 96 well plate can test up to 8 isolates.
117. Wrap the plate in parafilm and incubate at 37°C for 16–20 h.
118. The MIC corresponds to the final polymyxin B concentration in the first well where there is no bacterial growth.

**Note:** The expected polymyxin B MIC of the mgrB deletion mutant will be 8–32 μg/mL, with resistance defined as a MIC of >2 μg/mL.

**EXPECTED OUTCOMES**

Most genetic work studying multi-drug resistant Gram-negative bacteria has been performed in antibiotic susceptible laboratory strains of *K. pneumonia* (Cheng et al., 2016, 2018). However, antibiotic resistance frequently develops in a previously resistant strain (Jeannot et al., 2017). This single plasmid CRISPR-Cas9 / lambda red recombineering system allows for efficient and versatile genetic manipulation in MDR *K. pneumoniae*. Depending on the efficiency of the selected gRNA one should expect 50%–100% efficiency in obtaining the desired mutant, which is confirmed in the PCR reaction from step 102 and shown in Figure 4. The mutation will be inserted in a “scarless” manner so that only what is found on the homology cassette will be recombined into the genome. This will allow for more robust phenotypic work given minimal polar effects of the inserted mutations as well as allowing for serial rounds of editing and targeting of multiple loci.

**LIMITATIONS**

While zeocin is an effective antibiotic at high concentrations against most MDR *K. pneumoniae* isolates, resistance can develop de novo during growth of *K. pneumoniae*. As a result, there can be background colonies after transforming the CRISPR plasmid into *K. pneumoniae*. Therefore,
screening the resulting colonies for presence of the plasmid is critical prior to moving forward with the knockout / SNP editing protocol.

The use of restriction enzymes to generate the CRISPR plasmid does pose issues at times if a desired restriction site (AhdI, Bsal, XbaI) is found within the homology region to be used. We overcome this, at times, but deleting the area of the gene that contains the restriction site to make cloning easier. Additionally, we use alternative restrictions enzymes, including BamHI, if XbaI cannot be used to ligate the two homology arms together. The Gibson method of cloning would also be a potential option for cloning in the gRNA and the homology cassettes.

TROUBLESHOOTING

Problem 1
Difficulty amplifying the homology cassette or the gRNA cassette by PCR (steps 34–43).

Potential solution
In our experience almost all PCR reactions to assemble the CRISPR plasmids work well at an annealing temperature of 55°C. However, to determine the optimal annealing temperature for difficult PCR reactions we perform a gradient PCR first to optimize the annealing temperature.

Problem 2
Difficulty obtaining the full CRISPR plasmid after the ligation reaction with the pUC19_CRISPR vector, the gRNA cassette and the homology cassette (steps 49–61).

Potential solution
For ligation reactions that yield few or no colonies we take several steps to increase the efficiency of the reaction. First, we increase the concentration of the different components. For the vector we increase from approximately 100 ng of input to 200 ng of input. The molar ratio of the gRNA and homology will increase as well. Additionally, we ensure the ligation reaction lasts for at least 16–20 h at 16°C. We also ensure inactivation of the ligation reaction at 65°C for 10 min to remove the ligase from the formed plasmid and to improve the efficiency of the transformation. Finally, if these steps do not improve the yield of the ligation reaction we pool two aliquots of chemically competent Top10 cells and add 10 μL of the ligation reaction. If these troubleshooting steps still do not yield the desired plasmid, a Gibson assembly technique could be used.

Problem 3
Difficulty transforming the K. pneumoniae isolate of interest for genetic modification (steps 84–91).

Potential solution
Given the noted background found with zeocin as a resistance cassette, it can sometimes be difficult to isolate K. pneumoniae transformants that have taken up the CRISPR plasmid. To overcome this limitation, we initially add a higher concentration of the CRISPR plasmid to the electrocompetent stock of K. pneumoniae (up to 500 ng in 5 μL / 50 μL aliquot). If there are resulting colonies, but none of the selected colonies show uptake of the CRISPR plasmid via colony PCR we increase the concentration of zeocin in the transformation plates. For standard transformation reactions into carbapenem resistant ST258 K. pneumoniae we use a zeocin concentration of 1,000 μg/mL in LB, which can be increased to 1,250, 1,500 or even 2,000 μg/mL.

Problem 4
The induced culture grows as quickly as the control culture and no mutants are found after screening the resulting colonies (steps 96–103).
**Potential solution**
This may indicate overgrowth of a sub-population that developed zeocin resistance in vitro and subsequently lost the CRISPR plasmid due to the potential negative fitness effects of plasmid replication. This may also indicate inappropriate selection of a transformant that did not actually contain the CRISPR plasmid. We repeat the transformation reaction and identify additional K. pneumoniae colonies that have taken up the CRISPR plasmid and repeat the knockout protocol on these new colonies. If this troubleshooting does not work, it may indicate that the selected gRNA has little to no efficiency at inducing the double-strand break with the Cas9 protein. This occurs in approximately 5%–10% of our selected gRNA sequences. This appears to occur randomly and is not predictable by any of the aforementioned parameters for selecting appropriate N20 sequences. We then move forward with generating a second gRNA CRISPR plasmid. It is highly unlikely to select two gRNA sequences that are both non-functional.

**Problem 5**
There is differential growth of the induced cultures, and significantly fewer colonies on the induced plate, but all screened colonies are still wild type (steps 96–103).

**Potential solution**
This indicates that the gRNA and Cas9 combination are inducing the double-strand break, but the homologous recombination is occurring with minimal efficiency. This may be due to characteristics of the selected homology versus the timing of arabinose induction. We find that lengthening the induction time with arabinose from 6–8 h to at least 12 h, and at times up to 24–36 h, can help increase the number of resulting colonies that contain the desired mutation.

**RESOURCE AVAILABILITY**

**Lead contact**
Additional information and inquiries for additional reagents and resources are best directed to and will be handled by Dr. Anne-Catrin Uhlemann, au2110@columbia.edu

**Materials availability**
The pUC19_CRISPR_DpmrA plasmid necessary for this protocol is available at Addgene: catalog #160903.

**Data and code availability**
This study did not generate or analyze any new data sets or code.

**ACKNOWLEDGMENTS**
This work was funded through NIH/NIAID T32 Al100852-04 and K08 Al146284 (to T.H.M.), NIH/NIAID R01 Al116939, and NIH/NIDDK U54 DK104309 (to A.-C.U.)

**AUTHOR CONTRIBUTIONS**
T.H.M., M.J.G., and A.C.U. devised the initial CRISPR plasmid design. T.H.M. and M.J.G. completed the initial cloning to create the initial CRISPR plasmid. T.H.M. optimized the CRISPR knockout and SNP editing protocol.

**DECLARATION OF INTERESTS**
The authors declare no competing interests.
REFERENCES

Cheng, Y.H., Lin, T.L., Lin, Y.T., and Wang, J.T. (2016). Amino acid substitutions of Crb responsible for resistance to colistin through CrrC in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 60, 3709–3716.

Cheng, Y.H., Lin, T.L., Lin, Y.T., and Wang, J.T. (2018). A putative RND-type efflux pump, H239_3064, contributes to colistin resistance through Crb in Klebsiella pneumoniae. J. Antimicrob. Chemother. 73, 1509–1516.

El-Halfawy, O.M., Klett, J., Ingram, R.J., Loutet, S.A., Murphy, M.E., Martin-Santamaria, S., and Valvano, M.A. (2017). Antibiotic capture by bacterial lipocalins uncovers an extracellular mechanism of intrinsic antibiotic resistance. MBio 8, e00225-17.

Jeannot, K., Bolard, A., and Plesiat, P. (2017). Resistance to polymyxins in Gram-negative organisms. Int. J. Antimicrob. Agents 49, 526–535.

Jiang, W., Bikard, D., Cox, D., Zhang, F., and Marraffini, L.A. (2013). RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol. 31, 233–239.

Jiang, X., Zhu, C., Lin, J., Li, J., Fu, S., and Gong, H. (2016). Vector promoters used in Klebsiella pneumoniae. Biotechnol. Appl. Biochem. 63, 734–739.

Jiang, Y., Chen, B., Duan, C., Sun, B., Yang, J., and Yang, S. (2015). Multigene editing in the Escherichia coli genome via the CRISPR-Cas9 system. Appl. Environ. Microbiol. 81, 2506–2514.

Kovach, M.E., Elzer, P.H., Hill, D.S., Robertson, G.T., Farris, M.A., Roop, R.M., 2nd, and Peterson, K.M. (1995). Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 166, 175–176.

McConville, T.H., Annavajhala, M.K., Giddins, M.J., Macesic, N., Herrera, C.M., Ritzenberg, F.D., Bhushan, G.L., Ahn, D., Mancia, F., Trent, M.S., et al. (2020). Crb positively regulates high-level polymyxin resistance and virulence in Klebsiella pneumoniae. Cell Rep. 33, 108313.

Zhao, D., Yuan, S., Xiong, B., Sun, H., Ye, L., Li, J., Zhang, X., and Bi, C. (2016). Development of a fast and easy method for Escherichia coli genome editing with CRISPR/Cas9. Microb. Cell Fact. 15, 205.